- Home
- FBRX vs MCRB Comparison
FBRX vs MCRB Comparison
Compare FBRX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- MCRB
- Stock Information
- Founded
- FBRX N/A
- MCRB 2010
- Country
- FBRX United States
- MCRB United States
- Employees
- FBRX N/A
- MCRB N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- MCRB Health Care
- Exchange
- FBRX Nasdaq
- MCRB Nasdaq
- Market Cap
- FBRX 125.9M
- MCRB 131.0M
- IPO Year
- FBRX N/A
- MCRB 2015
- Fundamental
- Price
- FBRX $15.35
- MCRB $0.88
- Analyst Decision
- FBRX Strong Buy
- MCRB Buy
- Analyst Count
- FBRX 4
- MCRB 4
- Target Price
- FBRX $77.58
- MCRB $5.63
- AVG Volume (30 Days)
- FBRX 61.1K
- MCRB 2.0M
- Earning Date
- FBRX 11-14-2024
- MCRB 03-04-2025
- Dividend Yield
- FBRX N/A
- MCRB N/A
- EPS Growth
- FBRX N/A
- MCRB N/A
- EPS
- FBRX N/A
- MCRB N/A
- Revenue
- FBRX N/A
- MCRB $126,325,000.00
- Revenue This Year
- FBRX N/A
- MCRB N/A
- Revenue Next Year
- FBRX N/A
- MCRB N/A
- P/E Ratio
- FBRX N/A
- MCRB N/A
- Revenue Growth
- FBRX N/A
- MCRB 12856.41
- 52 Week Low
- FBRX $4.11
- MCRB $0.54
- 52 Week High
- FBRX $28.68
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- FBRX 41.80
- MCRB 54.44
- Support Level
- FBRX $14.66
- MCRB $0.72
- Resistance Level
- FBRX $17.00
- MCRB $0.91
- Average True Range (ATR)
- FBRX 2.62
- MCRB 0.07
- MACD
- FBRX -0.86
- MCRB -0.01
- Stochastic Oscillator
- FBRX 13.83
- MCRB 70.21
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.